0.00Open0.00Pre Close0 Volume0 Open Interest110.00Strike Price0.00Turnover130.38%IV-56.53%PremiumDec 20, 2024Expiry Date143.07Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9985Delta0.0001Gamma1.77Leverage Ratio-0.0218Theta0.0563Rho1.76Eff Leverage0.0028Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet